Nutex Health Inc.
Rank #100HypergrowthNUTX · Nasdaq · Healthcare
Nutex Health Inc. (NUTX) — Rank #100 by gross profitability (GP/assets 0.46) · ROE 18.0% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001479681 · all metrics point-in-time as of the filing date.
About
Nutex Health Inc. operates as a healthcare services and operations company in the United States.
Show moreShow less
It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc.
was founded in 2011 and is headquartered in Houston, Texas.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- nutexhealth.com
Financials
Strengthening
Direction over 5 fiscal years
- Free cash flown/a
- Gross marginimproving
- Gross profitabilityimproving
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-05 | 2024-12-31filed 2025-03-31 | 2023-12-31filed 2024-03-29 | 2022-12-31filed 2023-03-03 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 875.3 | 479.9 | 247.6 | 219.3 |
| Revenue growth (YoY) | 82.4% | 93.8% | 12.9% | -33.9% |
| Gross profit | 444.3 | 196.3 | 34.8 | 13.5 |
| Gross margin | 50.8% | 40.9% | 14.0% | 6.1% |
| Net income | 70.8 | 52.2 | (45.8) | (424.8) |
| Net margin | 8.1% | 10.9% | -18.5% | -193.7% |
| EPS (diluted) | $10.48 | $9.71 | -$0.07 | -$0.67 |
| EPS growth (YoY) | 7.9% | 13971.4% | 89.6% | — |
| Cash flow | ||||
| Operating cash flow | 248.1 | 23.2 | 1.3 | 50.6 |
| Capital expenditures | 2.5 | — | — | 14.6 |
| Free cash flow | 245.6 | — | — | 36.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?